Fundamental Data for CRME

CARDIOME P(NSDQ:CRME)

Cardiome Pharma Corp. is a product-focused cardiovascular drug development company with three late stage clinical drug programs focused on atrial arrhythmias, congestive heart failure, and hyperuricemia (gout). Cardiome''s lead antiarrhythmic product, RSD1235, is designed to be an acute-use, intravenous administration treatment for atrial fibrillation, a condition in which the atria of the heart beat rapidly and erratically. RSD1235 selectively blocks ion channels in the heart that are known to be active during episodes of atrial fibrillation.

# Employees: 0

Address: ,,,

Phone:

Fax:

Website:

Email:

Sector: Medical

Industry: MED-DRUGS

Executive Officers

No Information

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 4/5/2010

Mean EPS (Next Qtr): $0.08

Mean EPS (Year): ($0.19)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 8

Shares Performance

Period	CRME	Compare to S&P
YTD	-11.65 %	-26.89 %
4 Weeks	2.81 %	-2.40 %
12 Weeks	-7.80 %	-14.14 %

Shares Information

Analyst Coverage: Y

Avg Volume: 323228

Shares Outstanding: 64M

Market Cap: $0.26B

52 Week High: $5.53

52 Week Low: $2.62

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 1/1/1990 CRME split by factor of 0.100

Earnings Performance

EPS Growth in Last Quarter: 50.00 %

EPS Growth in Last Year: 94.12 %

Sales Growth in Last Quarter: 165.27 %

Sales Growth in Last Quarter: 3,977.75 %

Financials

Qtr Book Value: $19.81

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 9.360